{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:25:23Z","timestamp":1793849123222,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011823","name":"Education Department of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:23:41Z","timestamp":1784751821000},"page":"1112-1130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Safety Signals Following COVID-19 Vaccination in Children and Adolescents: A Nationwide VAERS Analysis, 2020\u20132025"],"prefix":"10.1016","volume":"48","author":[{"given":"Shasha","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s43856-024-00521-y","article-title":"Transmission risks of omicron Ba.5 following inactivated COVID-19 vaccines among children and adolescents in China","volume":"4","author":"Guo","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0002","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"Sars-Cov-2 vaccination and myocarditis in a nordic cohort study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the Bnt162b2 COVID-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clinthera.2026.06.011_bib0004","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of Mrna-1273 COVID-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.06.011_bib0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa2211031","article-title":"Evaluation of Bnt162b2 COVID-19 Vaccine in children younger than 5 years of age","volume":"388","author":"Mu\u00f1oz","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.011_bib0006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, Bbibp-Corv, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.clinthera.2026.06.011_bib0007","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamapediatrics.2023.1440","article-title":"Safety of the Bnt162b2 COVID-19 vaccine in children aged 5 to 17 years","volume":"177","author":"Hu","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0008","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-061894","article-title":"Safety of COVID-19 Mrna vaccination among young children in the vaccine safety datalink","volume":"152","author":"Goddard","year":"2023","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0009","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1038\/s41467-024-47745-z","article-title":"Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England","volume":"15","author":"Copland","year":"2024","journal-title":"Nat Commun"},{"issue":"36","key":"10.1016\/j.clinthera.2026.06.011_bib0010","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (Vaers)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.clinthera.2026.06.011_bib0011","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7144a3","article-title":"\"Safety monitoring of bivalent COVID-19 Mrna vaccine booster doses among persons aged \u226512 years - United States, August 31-October 23, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.011_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","article-title":"Safety Monitoring of COVID-19 vaccine booster doses among persons aged 12-17 years - United States, December 9, 2021-February 20, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1016\/j.clinthera.2026.06.011_bib0013","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15585\/mmwr.mm705152a1","article-title":"\"COVID-19 Vaccine safety in children aged 5-11 Years - United States, November 3-December 19, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"10.1016\/j.clinthera.2026.06.011_bib0014","doi-asserted-by":"crossref","first-page":"621","DOI":"10.15585\/mmwr.mm7223a2","article-title":"Safety Monitoring of Mrna COVID-19 vaccine third doses among children aged 6 months-5 years - United States, June 17, 2022-May 7, 2023","volume":"72","author":"Hause","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.011_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using Meddra: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.011_bib0016","first-page":"97","article-title":"Disproportionality analysis and causal inference in drug safety","volume":"39","author":"Scosyrev","year":"2025","journal-title":"Pharmaceut Med"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.011_bib0017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.011_bib0018","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40264-013-0075-1","article-title":"Choosing thresholds for statistical signal detection with the proportional reporting ratio","volume":"36","author":"Slattery","year":"2013","journal-title":"Drug Saf"},{"issue":"no. 7","key":"10.1016\/j.clinthera.2026.06.011_bib0019","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2527386","article-title":"Mining and disproportionality analysis of adverse events signals for Naltrexone based on real-world data from the Faers database","author":"Zeng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0021","article-title":"Post-Marketing Safety Profile of Meningococcal Group B Vaccines: a Real-World Disproportionality Analysis of the Vaers Database, 2015q1-2025q3","volume":"17","author":"Liang","year":"2026","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of Proportional reporting ratios (Prrs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.clinthera.2026.06.011_bib0023","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/RLU.0000000000005861","article-title":"Post-marketing safety evaluation of Lutathera (177 Lu-Dotatate) : a pharmacovigilance analysis of Fda adverse event reporting system","volume":"50","author":"Chen","year":"2025","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0024","article-title":"Musculoskeletal adverse events reported post-hepAtitis B vaccination in the vaccine adverse event reporting system","volume":"13","author":"Sun","year":"2025","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.011_bib0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14760584.2023.2292203","article-title":"Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system Data","volume":"23","author":"Li","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2550857","article-title":"Post-marketing safety monitoring of Rsv vaccines: a real-world study based on the vaccine adverse event reporting system (Vaers)","volume":"21","author":"Bao","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"7830","key":"10.1016\/j.clinthera.2026.06.011_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase i\/Ii study of COVID-19 Rna vaccine Bnt162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.clinthera.2026.06.011_bib0031","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.011_bib0032","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent Sars-Cov-2 variant vaccines: the phase 2 randomized open-label covail trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.011_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70151","article-title":"Safety Monitoring of bivalent COVID-19 Mrna vaccines among recipients 6\u2009months and older in the United States","volume":"34","author":"Lloyd","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0034","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/cid\/ciae420","article-title":"Safety and immunogenicity of an Mrna-1273 Booster in children","volume":"79","author":"Berthaud","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the Bnt162b2 COVID-19 vaccine in children 5 to 11 years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinthera.2026.06.011_bib0036","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases reported after Mrna-Based COVID-19 vaccination in the Us from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.clinthera.2026.06.011_bib0037","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"\"Myocarditis after Bnt162b2 Mrna vaccine against COVID-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinthera.2026.06.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005306","article-title":"Occurrence and features of childhood myocarditis: a Nationwide Study in Finland","volume":"6","author":"Arola","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.011_bib0039","article-title":"Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and Non-COVID-19 vaccine recipients","volume":"9","author":"Hajjo","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"Sars-Cov-2 vaccination and myocarditis in a Nordic Cohort Study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0041","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41541-023-00681-3","article-title":"Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 Bnt162b2 vaccination","volume":"8","author":"Katoto","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0042","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc2214450","article-title":"More on myocarditis after Bnt162b2 vaccination in Israeli adolescents","volume":"388","author":"Tovani-Palone","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.011_bib0043","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(22)00307-3","article-title":"Immunogenicity and reactogenicity of an inactivated Sars-Cov-2 vaccine (Bbv152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2\/3 study","volume":"22","author":"Vadrevu","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"10.1016\/j.clinthera.2026.06.011_bib0044","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of Mrna-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0045","article-title":"Mrna COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network Cohort Study","volume":"40","author":"Soe","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0046","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M21-3700","article-title":"Carditis after COVID-19 vaccination with a Messenger Rna Vaccine and an inactivated virus vaccine : a case-control study","volume":"175","author":"Lai","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.06.011_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004056","article-title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study","volume":"19","author":"Massari","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0048","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0049","first-page":"10","article-title":"Dysautonomia in children with post-acute sequelae of coronavirus 2019 disease and\/or vaccination","volume":"10","author":"Buchhorn","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"23","key":"10.1016\/j.clinthera.2026.06.011_bib0050","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after COVID-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0051","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamapediatrics.2022.4768","article-title":"Myopericarditis after COVID-19 Mrna vaccination among adolescents and young adults: a systematic review and meta-analysis","volume":"177","author":"Yasuhara","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.011_bib0052","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.radcr.2022.09.053","article-title":"Acute myocardial infarction complicated by severe left ventricle systolic dysfunction in a young patient after COVID 19 vaccination: a case report","volume":"18","author":"Boudihi","year":"2023","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0053","article-title":"Myocardial infarction or myocarditis? a case report and review of a myocardial adverse event associated with Mrna vaccine","volume":"10","author":"Badar\u00f3","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0054","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.hrthm.2023.09.012","article-title":"Postural orthostatic tachycardia syndrome after COVID-19 vaccination","volume":"21","author":"Teodorescu","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2023.103132","article-title":"Pooled Rates and Demographics of pots following Sars-Cov-2 infection versus COVID-19 vaccination: systematic review and meta-analysis","volume":"250","author":"Yong","year":"2023","journal-title":"Auton Neurosci"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0056","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.2023.0050","article-title":"Large cohort study finds possible association between postural orthostatic tachycardia syndrome and COVID-19 vaccination but far stronger link with Sars-Cov-2 infection","volume":"329","author":"Rubin","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clinthera.2026.06.011_bib0057","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.vaccine.2024.01.026","article-title":"\"Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous Bnt162b2 vaccinations in individuals 5-40 years of age","volume":"42","author":"Kumwichar","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.011_bib0058","article-title":"Fatal myocarditis following COVID-19 Mrna immunization: a case report and differential diagnosis review","volume":"12","author":"Sousa","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0059","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.23965","article-title":"Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: a systematic review","volume":"46","author":"Fatima","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103268","article-title":"Corrigendum to \"cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the myocarditis after COVID vaccination (Maciv) multicenter study\"","volume":"84","author":"Jain","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.clinthera.2026.06.011_bib0061","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/cid\/ciab707","article-title":"Intravenous injection of Coronavirus Disease 2019 (COVID-19) Mrna vaccine can induce acute myopericarditis in mouse model","volume":"74","author":"Li","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"27","key":"10.1016\/j.clinthera.2026.06.011_bib0062","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac239","article-title":"Acute necrotizing eosinophilic myocarditis after COVID-19 vaccination","volume":"43","author":"Ohtani","year":"2022","journal-title":"Eur Heart J"},{"issue":"40","key":"10.1016\/j.clinthera.2026.06.011_bib0063","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e286","article-title":"Myocarditis-induced sudden death after Bnt162b2 Mrna COVID-19 vaccination in Korea: case report focusing on histopathological findings","volume":"36","author":"Choi","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0064","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10875-021-01187-0","article-title":"First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-Biontech Mrna COVID-19 Vaccine (Bnt162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction","volume":"42","author":"Ameratunga","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1666509","article-title":"Comparative Safety Evaluation of pentavalent (Dtap-Ipv-Hib) and hexavalent (Dtap-Ipv-Hib-Hepb) vaccines in infants: a real-world analysis based on Vaers","volume":"15","author":"Wei","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0066","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.therap.2024.03.002","article-title":"Impact of the vaccination against Sars-Cov-2 campaign on disproportionality indicator from the who pharmacovigilance database: a competition bias study from case\/non-case analysis","volume":"79","author":"Adja\u00ef","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1664697","article-title":"Hpv vaccine-related thyroid adverse events: temporal patterns and reporting trends","volume":"16","author":"Song","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0068","doi-asserted-by":"crossref","DOI":"10.2196\/51007","article-title":"Adverse events of COVID-19 vaccines in the United States: temporal and spatial analysis","volume":"10","author":"Li","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0069","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.pcl.2020.07.014","article-title":"Risk factors for severity in children with Coronavirus Disease 2019: a comprehensive literature review","volume":"68","author":"Tsabouri","year":"2021","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242587","article-title":"Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges","volume":"16","author":"Rumain","year":"2021","journal-title":"PLoS One"},{"issue":"10441","key":"10.1016\/j.clinthera.2026.06.011_bib0071","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0072","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2022.04.024","article-title":"Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: a pragmatic approach","volume":"358","author":"Anastassopoulou","year":"2022","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.clinthera.2026.06.011_bib0073","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and Pericarditis After Vaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.clinthera.2026.06.011_bib0074","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hlc.2021.07.011","article-title":"Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination","volume":"30","author":"Pepe","year":"2021","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/1574886318666230329123459","article-title":"\"Myocarditis and pericarditis related to Mrna COVID-19 vaccination: a case report","volume":"19","author":"Mar\u00eda","year":"2024","journal-title":"Curr Drug Saf"},{"issue":"4","key":"10.1016\/j.clinthera.2026.06.011_bib0076","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/INF.0000000000003833","article-title":"\"Ventricular arrhythmia and COVID-19 vaccine-associated myocarditis","volume":"42","author":"Sheth","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.011_bib0077","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.vaccine.2020.12.046","article-title":"Myopericarditis after vaccination, vaccine adverse event reporting system (Vaers), 1990-2018","volume":"39","author":"Su","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0078","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31401-5","article-title":"Age and sex-specific risks of myocarditis and pericarditis following COVID-19 messenger Rna vaccines","volume":"13","author":"Le Vu","year":"2022","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.clinthera.2026.06.011_bib0079","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/CIRCULATIONAHA.125.074644","article-title":"Combined adaptive immune mechanisms mediate cardiac injury after COVID-19 vaccination","volume":"152","author":"Fanti","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.clinthera.2026.06.011_bib0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41541-025-01139-4","article-title":"Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination","volume":"10","author":"Cavalli","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.clinthera.2026.06.011_bib0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18505","article-title":"Epidemiology of myocarditis and pericarditis following Mrna vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0082","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s44161-025-00612-6","article-title":"The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after Sars-Cov-2 infection and COVID-19 vaccination","volume":"4","author":"Maatz","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0083","article-title":"Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: a Canadian Immunization Research Network study","volume":"70","author":"Pich\u00e9-Renaud","year":"2025","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.clinthera.2026.06.011_bib0084","first-page":"432","article-title":"Coxsackievirus B-3-induced myocarditis. effect of sex steroids on viremia and infectivity of cardiocytes","volume":"126","author":"Lyden","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101482","article-title":"Sex Differences in inflammation, redox biology, mitochondria and autoimmunity","volume":"31","author":"Di Florio","year":"2020","journal-title":"Redox Biol"},{"issue":"669","key":"10.1016\/j.clinthera.2026.06.011_bib0086","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate Manf and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.clinthera.2026.06.011_bib0087","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.clinthera.2026.06.011_bib0088","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.vaccine.2024.03.001","article-title":"Frequency and timing of adverse reactions to COVID-19 vaccines; a multi-country cohort event monitoring study","volume":"42","author":"Raethke","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.clinthera.2026.06.011_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2025.114642","article-title":"Active surveillance for myocarditis and pericarditis in Canadian Children from 2021 to 2022: a Canadian Immunization Monitoring Program active study","volume":"284","author":"Top","year":"2025","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.clinthera.2026.06.011_bib0090","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2352-4642(25)00247-0","article-title":"Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records","volume":"9","author":"Sampri","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"10.1016\/j.clinthera.2026.06.011_bib0091","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:35:05Z","timestamp":1793846105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002262"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Safety Signals Following COVID-19 Vaccination in Children and Adolescents: A Nationwide VAERS Analysis, 2020\u20132025","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}